SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-0.98%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$1.01B
AUM Growth
+$1.01B
(-8.4%)
Cap. Flow
+$4.34M
Cap. Flow
% of AUM
0.43%
Top 10 Holdings %
Top 10 Hldgs %
43.14%
Holding
161
New
32
Increased
25
Reduced
24
Closed
46
Top Buys
| 1 |
Pfizer
PFE
|
$47.6M |
| 2 |
Eli Lilly
LLY
|
$38.5M |
| 3 |
AbbVie
ABBV
|
$24.8M |
| 4 |
Palo Alto Networks
PANW
|
$14.8M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$11.5M |
Top Sells
| 1 |
Merck
MRK
|
$60.1M |
| 2 |
Johnson & Johnson
JNJ
|
$26.9M |
| 3 |
LivePerson
LPSN
|
$14.2M |
| 4 |
Generac Holdings
GNRC
|
$13.6M |
| 5 |
Amazon
AMZN
|
$12.8M |
Sector Composition
| 1 | Healthcare | 74.46% |
| 2 | Technology | 12.76% |
| 3 | Industrials | 4.7% |
| 4 | Financials | 3.69% |
| 5 | Communication Services | 1.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$657B
| $80.5M | 6.76% | 348,495 +166,600 | +92% | +$38.5M |
|
2
AstraZeneca
AZN
$248B
| $77.6M | 6.52% | 1,291,667 +143,994 | +13% | +$8.65M |
|
|
3
AbbVie
ABBV
$372B
| $64.3M | 5.4% | 596,294 +230,100 | +63% | +$24.8M |
|
|
4
Pfizer
PFE
$141B
| $47.6M | 4% | +1,106,528 | New | +$47.6M |
|
5
Sanofi
SNY
$121B
| $40.7M | 3.42% | 843,400 | – | – |
|
|
6
Johnson & Johnson
JNJ
$427B
| $38.6M | 3.24% | 238,948 -166,660 | -41% | -$26.9M |
|
|
7
Generac Holdings
GNRC
$10.9B
| $29M | 2.44% | 71,013 -33,350 | -32% | -$13.6M |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $21.1M | 1.77% | 359,260 +99,365 | +38% | +$5.84M |
|
9
Microsoft
MSFT
$3.77T
| $19M | 1.6% | 67,536 | – | – |
|
10
C4 Therapeutics
CCCC
$185M
| $17.1M | 1.43% | 381,774 -136,837 | -26% | -$6.11M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $15.7M | 1.32% | 247,917 +52,800 | +27% | +$3.35M |
|
12
Zai Lab
ZLAB
$3.68B
| $15.4M | 1.29% | 145,982 +48,036 | +49% | +$5.06M |
|
|
13
Palo Alto Networks
PANW
$127B
| $14.8M | 1.25% | +31,000 | New | +$14.8M |
|
14
Kura Oncology
KURA
$686M
| $14.8M | 1.24% | 788,735 -80,151 | -9% | -$1.5M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $14.3M | 1.21% | 750,603 +203,416 | +37% | +$3.89M |
|
16
SolarEdge
SEDG
$2.01B
| $13.3M | 1.11% | 50,000 +17,800 | +55% | +$4.72M |
|
17
Fate Therapeutics
FATE
$120M
| $13M | 1.09% | 219,299 +54,000 | +33% | +$3.2M |
|
18
Altimmune
ALT
$338M
| $12.3M | 1.03% | 1,088,854 +405,459 | +59% | +$4.59M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $12.2M | 1.03% | 494,809 +116,167 | +31% | +$2.86M |
|
20
Werewolf Therapeutics
HOWL
$59.9M
| $11.8M | 0.99% | 688,475 -17,819 | -3% | -$306K |
|
21
Meta Platforms (Facebook)
META
$1.86T
| $11.7M | 0.98% | 34,400 +7,400 | +27% | +$2.51M |
|
22
Crinetics Pharmaceuticals
CRNX
$2.92B
| $11.5M | 0.97% | 548,643 -85,445 | -13% | -$1.8M |
|
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.5M | 0.97% | +149,017 | New | +$11.5M |
|
24
Twilio
TWLO
$16.2B
| $11.3M | 0.95% | 35,500 +9,000 | +34% | +$2.87M |
|
25
Nice
NICE
$8.73B
| $10.7M | 0.9% | 37,786 -39,000 | -51% | -$11.1M |
|